Antiangiogenesis to curb urothelial cancer
Mené dans 23 pays sur 530 patients atteints d'un carcinome urothélial de stade localement avancé ou métastatique, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du ramucirumab au paclitaxel, après l'échec d'une chimiothérapie à base de sels de platine
Angiogenesis has been associated with clinicopathological factors and features of biological aggressiveness in urothelial cancer.1,2 Although several agents targeting the vascular endothelial growth factor (VEGF) pathway have been investigated in phase 1 and 2 trials in advanced urothelial cancer and as maintenance,1,3–5 the overall clinical benefit has been small, with occasional disease stabilisation seen in some patients.1,3
The Lancet , commentaire, 2016